Global healthcare communications
Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy
In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will...
On GLOBE Final Rule
The publication of the GLOBE Final Rule provides important clarity on the administration's approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally....
Join Genesis Research Group’s October webinar: ‘From scoping to systematic: Choosing the right literature review for your evidence needs’.
On Tuesday, 6 October 2026, Genesis Research Group’s evidence synthesis, HEOR, and evidence planning teams will be presenting an expert webinar on the topic of selecting the right literature review.
Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR
Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence...
Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it...
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on...
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...
Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.
Insights From ISPOR 2025: Breaking the Data Barrier in Rare Diseases – Can AI Bridge the Gap?
Last month, the ISPOR annual meeting in Montreal was brimming with opportunities to explore the latest developments and insights in health economics and outcomes research (HEOR) and market access. In...
Sustainability and Environmental Impact in Market Access and Health Economics
As the concept of sustainability gains traction in healthcare, it is beginning to influence how value is assessed and communicated across the Pharmaceutical and Medtech industries. In this article, experts...
Insights From ISPOR 2025: R In Health Technology Assessment – Is It The Future?
ISPOR’s annual meeting in Montreal this May was packed with opportunities to explore the latest trends, insights, and research in HEOR and market access. In this series, our experts share...
Petauri unites Mtech Access and Delta Hat under one team: Petauri Evidence
Rapidly growing pharmaceutical services platform unveils new integrated structure for global evidence solutions.